UBS’s Revance Therapeutics, Inc. RVNC Stock Holding History

UBS’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-1,622	Closed	-$55K	–	10838
2014 Q2	$55K	Buy	1,622 +1,615	+23,071%	+$50.6K	﹤0.01%	6740
2014 Q1	$0	Buy	+7	New	+$219	﹤0.01%	10895

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

UBS's RVNC Position: Q3 2014 in Review

UBS sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2014, closing a stake of 1,622 shares — an estimated $55K sold.

UBS first reported a position in RVNC in Q1 2014 and held it in 2 quarters. The position peaked at $55K in Q2 2014. 80 funds tracked by Wall St. Rank hold RVNC as of Q3 2014.

UBS reported no remaining Revance Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
UBS sold 1,622 Revance Therapeutics, Inc. shares in Q3 2014, an estimated $55K.
UBS first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 2 quarters.
UBS's Revance Therapeutics, Inc. position peaked at $55K in Q2 2014.
80 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.